USPTO Examiner LEE SIN J - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18676396ATROPINE-CONTAINING AQUEOUS COMPOSITIONMay 2024December 2025Abandon1820NoNo
18598292WOOD TREATMENT SOLUTIONS CONTAINING FUNGICIDES AND TERTIARY ALKANOLAMINES AND RELATED METHODS, WOOD PRODUCTS AND COMPOSITION FOR PROTECTION AGAINST FUNGAL ORGANISMSMarch 2024July 2025Allow1720NoNo
18402960SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFENJanuary 2024July 2025Allow1820NoNo
18392543HYDROGEL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF PEDIATRIC GROWTH PLATE INJURIESDecember 2023May 2025Allow1611YesNo
18532596MODIFIED-RELEASE DOSAGE FORMS OF RUXOLITINIBDecember 2023August 2024Abandon910NoNo
18522062ORAL PATCH FOR TREATING MOUTH ULCERSNovember 2023August 2024Allow820YesNo
1838558910-(2-HYDROXYETHYL)-9-(2-HYDROXYPYRIDIN-3-YL)-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow510NoNo
18496388Anti-Dandruff CompositionOctober 2023October 2025Allow2420NoNo
18383987PH STABILIZED TOPICAL OPHTHALMIC COMPOSITIONSOctober 2023February 2026Abandon2840NoNo
18372162Therapeutic Composition and MethodsSeptember 2023October 2024Allow1311NoNo
18244734COMPOSITION AND THERAPY FOR TREATMENT OF GAG REFLEXESSeptember 2023February 2026Abandon2931NoNo
18461665PHARMACEUTICAL FORMULATIONS OF PHLOROGLUCINOL AND TRIMETHYLPHLOROGLUCINOLSeptember 2023February 2026Abandon3010NoNo
18240528ODOR ELIMINATING COMPOSITION WITH MORPHOLINIUM AND ALGINATE COMPOUNDSAugust 2023February 2026Abandon3010NoNo
18238743COMPOSITIONS COMPRISING WATER THAT EXHIBITS INCREASED CELL PERMEABILITY AND METHODS OF USE THEREOFAugust 2023October 2024Abandon1420NoNo
18269379PHARMACEUTICAL COMPOSITION COMPRISING TADALAFIL OR PHARMACEUTICALLLY ACCEPTABLE SALT THEREOF AND DUTASTERIDE OR PHARMACEUTICALLLY ACCEPTABLE SALT THEREOF EXHIBITING NOVEL DISSOLUTION RATEJune 2023February 2026Allow3210NoNo
18339972PREPARATION METHOD OF AMISULPRIDE TABLETJune 2023February 2026Allow3210NoNo
18335575FIBROUS PELLET FOR ORAL APPLICATIONS AND METHODS THEREOFJune 2023January 2026Abandon3210NoNo
18199974Oleogel having a protein microstructure with optimized oil release properties for replacing structured fats and saturated oils in food and cosmetic productsMay 2023November 2023Allow510YesNo
18321644VAGINAL CARE COMPOSITIONS AND METHODS OF IMPROVING VAGINAL HEALTHMay 2023November 2023Allow620YesNo
18304269CURCUMINOID COMPOSITESApril 2023October 2025Allow3010NoNo
18297135Personal Care CompositionsApril 2023April 2024Allow1220NoNo
18248218ANTIPERSPIRANT COMPOSITIONApril 2023December 2025Allow3220NoNo
18163912MANUFACTURING DEVICE FOR GELATIN CAPSULEFebruary 2023March 2026Allow3710NoNo
18007282PHARMACEUTICAL FORMULATIONS COMPRISING TADALAFILJanuary 2023February 2026Allow3710NoNo
18151382PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND DERIVATIVES THEREOF AND A STATINJanuary 2023February 2025Abandon2520NoNo
18009554HAEMOSTATIC MATERIALDecember 2022July 2025Abandon3110NoNo
18075150MODIFIED-RELEASE DOSAGE FORMS OF RUXOLITINIBDecember 2022January 2024Abandon1320NoNo
18060929PHARMACEUTICAL FORMULATIONDecember 2022August 2024Abandon2120NoNo
17994720Therapeutic Composition And MethodsNovember 2022September 2023Allow910NoNo
17987929PHARMACEUTICAL COMPOSITIONS CONTAINING MIXED POLYMERIC MICELLESNovember 2022December 2023Allow1310NoNo
17924781PERCUTANEOUS ABSORPTION PREPARATION COMPRISING DONEPEZIL WITH IMPROVED STABILITYNovember 2022October 2025Allow3510NoNo
17924202FIBROUS LAYER HAVING HYDROPHILIC PROPERTIES AND A FABRIC COMPRISING SUCH LAYERNovember 2022November 2025Abandon3601NoNo
17980516OXYGEN GENERATING FACE MASKSNovember 2022November 2023Abandon1310NoNo
17979506THERMO-RESPONSIVE HYDROGEL FOR INTRATUMORAL ADMINISTRATION AS A TREATMENT IN SOLID TUMOR CANCERSNovember 2022January 2025Allow2730NoNo
17969554ANTIBIOTIC FORMULATIONS FOR LOWER BACK PAINOctober 2022August 2024Allow2220YesNo
17995748GRANULES COMPRISING SURFACE-REACTED CALCIUM CARBONATE AS EXCIPIENTOctober 2022October 2025Abandon3701NoNo
17916903VISCOUS COMPOSITIONOctober 2022September 2025Abandon3510NoNo
17937660COMPOSITION AND THERAPY FOR TREATMENT OF GAG REFLEXESOctober 2022March 2023Allow510NoNo
17937665COMPOSITION AND THERAPY FOR TREATMENT OF GAG REFLEXESOctober 2022June 2023Allow920YesNo
17947711Compositions Containing Verteporfin, Ribavirin, Gemcitabine, or Combinations Thereof and Methods of Use for Treating COVID-19, Cancer, or Non Cancer DiseasesSeptember 2022October 2023Allow1320NoNo
17802314WASH COMPOSITION SUBSTANTIALLY FREE OF OILAugust 2022June 2025Allow3420NoNo
17888611SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFENAugust 2022April 2024Abandon2030NoNo
17888737SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFENAugust 2022April 2024Abandon2030NoNo
17884496FOAMING BODY DEODORIZERAugust 2022January 2024Abandon1710NoNo
17760269DISSOLVING AGENTAugust 2022June 2025Abandon3410NoNo
17882223SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFENAugust 2022March 2024Abandon1930NoNo
17881785SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFENAugust 2022March 2024Abandon1940YesNo
17760108DEODORANTAugust 2022September 2025Allow3820YesNo
17879267Method of treating urolithiasisAugust 2022November 2023Allow1620NoNo
17879285Methods of manufacturing microspheresAugust 2022July 2023Allow1210NoNo
17815019LIQUID ORAL PHARMACEUTICAL DOSAGE FORMJuly 2022May 2024Abandon2120NoNo
17815046WOOD TREATMENT SOLUTIONS CONTAINING FUNGICIDES AND TERTIARY ALKANOLAMINES AND RELATED METHODS, WOOD PRODUCTS AND COMPOSITION FOR PROTECTION AGAINST FUNGAL ORGANISMSJuly 2022January 2024Allow1820NoNo
17864695COMPOSITION FOR LIP PAIN RELIEF AND METHOD OF MAKINGJuly 2022December 2024Abandon2920NoNo
17809661METHOD FOR REMOVING KERATOTIC PLUGSJune 2022January 2024Allow1820YesNo
17786198GEL COMPOSITIONS FOR MITIGATION OF BURN INJURIES, KITS CONTAINING THE GEL COMPOSITIONS, AND ASSOCIATED METHODSJune 2022September 2025Abandon3901NoNo
17832263METHODS FOR PREVENTING AND TREATING RESPIRATORY INFECTIONS VIA MODIFICATION OF VIRUS RECEPTOR BINDING DOMAINS USING HYPOHALOUS ACIDSJune 2022September 2025Abandon3930NoNo
17743262Personal Care CompositionsMay 2022June 2024Allow2530NoNo
17776486COMPOSITION FOR ANTIMICROBIAL PHOTODYNAMIC THERAPYMay 2022October 2025Abandon4111NoNo
17739862Process for the preparation of angiotensin receptor blockers or pharmaceutically acceptable salts thereofMay 2022November 2022Allow610NoNo
17775071ANTIPERSPIRANT FORMULATIONS COMPRISING HEMISQUALANEMay 2022May 2025Abandon3640NoNo
17736291SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFENMay 2022September 2023Abandon1630YesNo
17735667SPRAYABLE COSMETIC COMPOSITION COMPRISING POLYGLYCEROL ESTERSMay 2022September 2023Abandon1710NoNo
17734193FOAM COMPOSITIONSMay 2022March 2025Abandon3440NoNo
17734188FOAM COMPOSITIONSMay 2022November 2025Allow4260YesNo
17730500PERSONAL CARE COMPOSITIONS WITH CYSTINEApril 2022January 2023Allow900NoNo
17727510COMPOSITIONS COMPRISING INDIGO AND/OR AN INDIGO DERIVATIVE AND METHODS OF USE THEREOFApril 2022February 2025Abandon3440NoNo
17725923SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFENApril 2022June 2022Allow200NoNo
17719283Gel Texturizer Base for CosmeticsApril 2022July 2024Allow2720NoNo
17640923A METHOD OF PREPARING POLYMERIC MICROPARTICLES, POLYMERIC MICROPARTICLES, MEDICAL COMPOSITION, COSMETIC COMPOSITION, MEDICAL ARTICLES AND COSMETIC ARTICLES USING THE SAMEMarch 2022February 2025Allow3510NoNo
17640448FOOD COMPOSITIONS FOR LACTATING WOMENMarch 2022April 2025Abandon3710NoNo
17686198UNDERARM TONERMarch 2022September 2023Allow1920YesNo
17682033RESPIRATORY TRACT DELIVERY OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR FOR TREATMENT OF PARKINSON'S DISEASEFebruary 2022February 2023Allow1210YesNo
17681705HYDROGEN SULFIDE AND NITRIC OXIDE THERAPY FOR COVID-19 INFECTIONFebruary 2022November 2024Abandon3311NoNo
17635342METHOD FOR THE DECOLORIZATION OF KERATIN MATERIAL THAT HAS BEEN DYED USING AN ORGANOSILICON COMPOUND AND A PIGMENTFebruary 2022May 2025Abandon3910NoNo
17665313IODINE COMPOSITIONSFebruary 2022July 2023Allow1720YesNo
17632174Oral Care Compositions and Methods of UseFebruary 2022January 2026Allow4830YesNo
17632182Compositions and Related MethodsFebruary 2022January 2026Allow4730NoNo
17625688ANTIBACTERIAL GLASS COMPOSITION AND MANUFACTURING METHOD THEREOFJanuary 2022July 2025Allow4220NoNo
17553425NO-RINSE MAKEUP REMOVAL COMPOSITIONDecember 2021May 2024Allow2920NoNo
17619324Ruthenium (II) Complexes and Conjugates Thereof for Use as Photosensitizer Agent in Photodynamic TherapyDecember 2021January 2026Allow4921NoNo
17549491METHOD FOR USING MUSTARD MEAL OR AN EXTRACT THEREOFDecember 2021January 2025Abandon3710NoNo
17547045SILICONE OIL-FREE ANTIPERSPIRANTSDecember 2021November 2023Abandon2320NoNo
17614156EXTERNAL PREPARATIONNovember 2021November 2024Abandon3610NoNo
17534752ATTRACTANTS FOR RATSNovember 2021January 2023Allow1430NoNo
17613670PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HBVNovember 2021February 2025Abandon3801NoNo
17607053ETHANOL HARDENER AND USE THEREOFOctober 2021November 2024Allow3711NoNo
17452227SELF-EMULSIFYING FORMULATION OF BISPHOSPHONATES AND ASSOCIATED DOSAGE FORMSOctober 2021August 2024Abandon3410NoNo
17605418PREBIOTIC SKIN CARE COMPOSITIONS CONTAINING CARBOXYLIC ACIDSOctober 2021December 2024Allow3820NoNo
17603015LIPID PHARMACEUTICAL PREPARATION AND APPLICATION THEREOFOctober 2021May 2025Allow4310NoNo
17603163NEW DELIVERY SYSTEM FOR POLYUNSATURATED FATTY ACIDSOctober 2021August 2025Allow4620NoYes
17496056CARE COMPOSITION AND USE THEREOFOctober 2021May 2025Allow4330YesNo
17601545DENTAL COMPOSITIONOctober 2021February 2025Abandon4110NoNo
17491651METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDSOctober 2021December 2025Abandon5011NoNo
17472551PREPARATION FOR TREATING BODY ODORSeptember 2021January 2025Abandon4040NoNo
17446663Compressible Cannabinoid Pharmaceutical CompositionSeptember 2021December 2024Abandon3910NoNo
17409003ORAL PHARMACEUTICAL COMPOSITIONS OF LOSARTAN OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOFAugust 2021December 2022Abandon1630YesNo
17423350AN ANTIMICROBIAL MIXTUREJuly 2021July 2025Abandon4830YesNo
17305357FOAMING MIXED ALCOHOL/WATER COMPOSITIONS COMPRISING A STRUCTURED ALKOXYLATED SILOXANEJuly 2021July 2025Allow4850NoNo
17354181Natural Hydrocarbon/Ester Compositions with Improved Sensory PropertiesJune 2021August 2025Allow5050YesNo
17415272AN ANTIPERSPIRANT COMPOSITION COMPRISING INORGANIC POLYIONIC CLUSTERJune 2021October 2024Allow4020NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, SIN J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
5
Examiner Affirmed
3
(60.0%)
Examiner Reversed
2
(40.0%)
Reversal Percentile
60.8%
Higher than average

What This Means

With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
16
Allowed After Appeal Filing
4
(25.0%)
Not Allowed After Appeal Filing
12
(75.0%)
Filing Benefit Percentile
33.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LEE, SIN J - Prosecution Strategy Guide

Executive Summary

Examiner LEE, SIN J works in Art Unit 1613 and has examined 313 patent applications in our dataset. With an allowance rate of 62.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner LEE, SIN J's allowance rate of 62.3% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LEE, SIN J receive 2.63 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LEE, SIN J is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +23.2% benefit to allowance rate for applications examined by LEE, SIN J. This interview benefit is in the 69% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.8% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.5% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 68.8% of appeals filed. This is in the 54% percentile among all examiners. Of these withdrawals, 72.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 69.4% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 67% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.